公开(公告)号：US11040077B2

公开(公告)日：2021-06-22

申请号：US16885152

申请日：2020-05-27

申请人： DermBiont, Inc.

发明人： Robert M. Brucker ,  Xuecheng Zhang ,  Ida Lister ,  Sanjay Jain

IPC分类号： A61K35/747 ,  A61P31/04 ,  A61K8/99 ,  A61K9/00 ,  A61K35/741 ,  A61K35/744 ,  A61Q17/04 ,  A61Q19/08

摘要： Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

公开(公告)号：US20200345799A1

公开(公告)日：2020-11-05

申请号：US16885152

申请日：2020-05-27

申请人： DermBiont, Inc.

发明人： Robert M. Brucker ,  Xuecheng Zhang ,  Ida Lister ,  Sanjay Jain

IPC分类号： A61K35/747 ,  A61K9/00 ,  A61K35/744 ,  A61K35/741 ,  A61Q17/04 ,  A61P31/04 ,  A61K8/99 ,  A61Q19/08

摘要： Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

公开(公告)号：US20210361725A1

公开(公告)日：2021-11-25

申请号：US17243509

申请日：2021-04-28

申请人： DermBiont, Inc.

发明人： Robert M. Brucker ,  Xuecheng Zhang ,  Ida Lister ,  Sanjay Jain

IPC分类号： A61K35/747 ,  A61P31/04 ,  A61K8/99 ,  A61K9/00 ,  A61K35/741 ,  A61K35/744 ,  A61Q17/04 ,  A61Q19/08

摘要： Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

公开(公告)号：US12064459B2

公开(公告)日：2024-08-20

申请号：US17243509

申请日：2021-04-28

申请人： DermBiont, Inc.

发明人： Robert M. Brucker ,  Xuecheng Zhang ,  Ida Lister ,  Sanjay Jain

IPC分类号： A61K35/747 ,  A61K8/49 ,  A61K8/99 ,  A61K9/00 ,  A61K35/741 ,  A61K35/744 ,  A61P17/00 ,  A61P31/04 ,  A61Q17/04 ,  A61Q19/08

CPC分类号： A61K35/747 ,  A61K8/492 ,  A61K8/99 ,  A61K9/0014 ,  A61K35/741 ,  A61K35/744 ,  A61P17/00 ,  A61P31/04 ,  A61Q17/04 ,  A61Q19/08

摘要： Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

公开(公告)号：US20220160617A1

公开(公告)日：2022-05-26

申请号：US17602708

申请日：2020-04-09

申请人： DermBiont, Inc.

发明人： Robert M. Brucker ,  Xuecheng Zhang ,  Ida Lister ,  Sanjay Jain

IPC分类号： A61K8/99 ,  A61K35/747 ,  A61K8/49 ,  A61P17/00 ,  A61Q17/04 ,  A61Q19/08

摘要： Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

公开(公告)号：US20210386802A1

公开(公告)日：2021-12-16

申请号：US17384598

申请日：2021-07-23

申请人： DermBiont, Inc.

发明人： Robert M. Brucker ,  Xuecheng Zhang ,  Ida Lister ,  Sanjay Jain

IPC分类号： A61K35/747 ,  A61Q17/04 ,  A61K35/741 ,  A61P31/04 ,  A61Q19/08 ,  A61K9/00 ,  A61K8/99 ,  A61K35/744

摘要： Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.